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Background. To overcome some of the limitations of conventional microbiologic techniques, polymerase chain
reaction (PCR)–based assays are proposed as useful tools for the diagnosis of visceral leishmaniasis.
Patients and methods. A comparative study using conventional microbiologic techniques (i.e., serologic testing,
microscopic examination, and culture) and a Leishmania species–specific PCR assay, using peripheral blood and
bone marrow aspirate samples as templates, was conducted during an 8-year period. The study cohort consisted
of 594 Italian immunocompetent (adult and pediatric) and immunocompromised (adult) patients experiencing
febrile syndromes associated with hematologic alterations and/or hepatosplenomegaly. Identification of the infecting
protozoa at the species level was directly obtained by PCR of peripheral blood samples, followed by restriction
fragment–length polymorphism analysis of the amplified products, and the results were compared with those of
isoenzyme typing of Leishmania species strains from patients, which were isolated in vitro.
Results. Sixty-eight patients (11.4%) had a confirmed diagnosis of visceral leishmaniasis. Eleven cases were
observed in human immunodeficiency virus (HIV)–uninfected adults, 20 cases were observed in HIV-infected
adults, and the remaining 37 cases were diagnosed in HIV-uninfected children. In the diagnosis of primary visceral
leishmaniasis, the sensitivities of the Leishmania species–specific PCR were 95.7% for bone marrow aspirate samples
and 98.5% for peripheral blood samples versus sensitivities of 76.2%, 85.5%, and 90.2% for bone marrow aspirate
isolation, serologic testing, and microscopic examination of bone marrow biopsy specimens, respectively. None of
229 healthy blood donors or 25 patients with imported malaria who were used as negative control subjects had
PCR results positive for Leishmania species in peripheral blood samples (i.e., specificity of Leishmania species–
specific PCR, 100%). PCR and restriction fragment–length polymorphism analysis for Leishmania species iden-
tification revealed 100% concordance with isoenzyme typing in the 19 patients for whom the latter data were
available.
Conclusions. PCR assay is a highly sensitive and specific tool for the diagnosis of visceral leishmaniasis in both
immunocompetent and immunocompromised patients and can be reliably used for rapid parasite identification
at the species level.
Visceral leishmaniasis (VL) is a systemic, vector-borne
parasitic disease caused by obligate intracellular pro-
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tozoa of the genus Leishmania and transmitted by the
bite of sandflies. The disease is endemic in 62 countries
worldwide [1], with a total of 200 million people at
risk, and it is fatal if not diagnosed and left untreated.
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Table 1. Demographic characteristics of and diagnostic findings in 68 consecutive patients with visceral leishmaniasis.
Variable
Group A
(n p 11)
Group B
(n p 20)
Group C
(n p 37)
Total
(n p 68)
Sex
Male 10 16 15 41
Female 1 4 22 27
Age, median value (range) 49 years
(32–72 years)
38.5 years
(27–47 years)
15 months
(4–156 months)
Lymphocyte CD4+ cell count, median cells/mL (range) NP 81 (4–190) NP NP
Positive Leishmania serologic test result 5/7 (71.4) 11/18 (61.1) 37/37 (100) 53/62 (85.5)
Positive findings of microscopic examination of BMA sample 9/10 (90) 14/15 (93.3) 32/36 (88.8) 55/61 (90.2)
Positive BMA culture 3/3 (100) 6/9 (62.5) 23/30 (76.6) 32/42 (76.2)
Positive PB culture NP 3/4 (75) NP 3/4 (75)
Positive result of PCR of PB sample 11/11 (100) 20/20 (100) 33/34 (97.1) 64/65 (98.5)
Positive result of PCR of BMA sample 5/5 (100) 13/14 (92.8) 27/28 (96.4) 45/47 (95.7)
NOTE. Data are no. (%) of patients, unless otherwise indicated. Group A includes HIV-uninfected adults, group B includes HIV-infected adults, and group C
includes HIV-uninfected children. BMA, bone marrow aspirate; NP, not performed; PB, peripheral blood.
VL is caused by the Leishmania donovani complex, which in-
cludes the following 3 species with partly overlapping geo-
graphical distribution: L. donovani (found in India and Africa),
Leishmania infantum (found in the Mediterranean basin, the
Middle East, and Asia), and Leishmania chagasi (found in South
America), which is now considered to be identical to L. infan-
tum [2].
VL is characterized by prolonged fever, weight loss, pro-
gressive anemia or pancytopenia, and hypergammaglobuline-
mia. The diagnosis of VL is traditionally based on serologic
testing results and the direct demonstration of Leishmania par-
asites by microscopic examination and in vitro isolation [3].
Accepted limits of Leishmania serologic testing are reduced
sensitivity in patients with severe underlying immunosuppres-
sion, the absence of discriminating power between active or
past infections, and, consequently, lack of value in monitoring
the parasitological response to specific therapy. On the other
hand, microscopic examination requires invasive procedures,
such as spleen and bone marrow aspiration (BMA). Splenic
aspirate cytologic testing has an excellent sensitivity (95%) but
is associated with the risk of severe complications when per-
formed by inexperienced health care workers. The sensitivity
of microscopic examination of BMA samples varies among
different studies from 60% to 85% [3]. Finally, in vitro parasite
isolation still remains the reference method to unequivocally
identify the parasite at the species level, but it is expensive,
cumbersome, and generally unhelpful in clinical practice be-
cause of the long duration of time (days to weeks) required to
obtain a definitive result.
In the past decade, PCR has been increasingly used to detect
Leishmania DNA in clinical samples, such as BMA and pe-
ripheral blood (PB) samples, for the diagnosis of VL and for
parasite species characterization. Several target sequences, such
as ribosomal RNA (rRNA) genes, the mini-exon derived RNA
gene, the kinetoplast minicircles, and repetitive nuclear DNA
sequences, have been used in published PCR assays [4–11]. In
the present study, we performed a comparative analysis of mi-
croscopic, serologic, and PCR-based diagnostic methods for
detection of Leishmania species in a consecutive series of 68
adult and pediatric cases of VL that were observed in both
immunocompetent and immunocompromised Italian patients.
PATIENTS AND METHODS
An 8-year prospective study was performed in Milan (Lom-
bardy region, northern Italy) and Palermo (Sicily region, south-
ern Italy) from January 1997 through January 2005. Five hun-
dred ninety-four consecutive patients living in the
Mediterranean area in Italy who presented with clinical signs
and symptoms compatible with VL were included in the study.
All VL cases were confirmed by serologic testing, direct ex-
amination, and/or culture (at least 1 positive criteria was re-
quired for confirmation)
The majority of patients enrolled at the Department of In-
fectious and Tropical Diseases at the L. Sacco University Hos-
pital of Milan were HIV-positive adults (447 patients; 83.5%),
and the individuals who were observed at the Institute of In-
fectious Pathology and Virology at the G. di Cristina Hospital
of Palermo were exclusively immunocompetent children (55
children). In addition, 254 control subjects were studied to
assess the specificity of the PCR assay. These included 229
healthy blood donors who were recruited from the Immune-
Hematology Department of L. Sacco Hospital and 25 patients
with a confirmed diagnosis of imported malaria.
Molecular studies. Details of specimen collection, pro-
cessing, DNA extraction, and qualitative and semiquantitative
PCR amplification of a 359–base pair fragment of the small
rRNA gene of Leishmania species are described elsewhere [4,
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Table 2. Reported sensitivities and specificities of different PCR protocols in the diagnosis of visceral leishmaniasis.
Study (year) Study cohort
No. of
patients
with VL
Type of PCR (bp):
Leishmania species
Sensitivity of PCR, %
Specificity,
%Whole blood specimen
BMA
specimen
Adhya et al. [15] (1995) 39 Indian patients 31 MedRNA (180 bp):
Leishmania donovani
96.8 NR 100
Nuzum et al. [16] (1995) 63 Indian, Kenyan, and
Brazilian patients
63 kDNA (nr): L. donovani 90a NR 100
Mathis et al. [17] (1995) 51 Swiss patients (43
with HIV infection)
11 ssU-rRNA (603 bp):
Leishmania species
72.7 100 100
Piarroux et al. [19] (1996) 252 French Id patients
with HIV infection
50 Repetitive nuclear
sequence (140 bp):
Leishmania infantum
NR 84 99
Costa et al. [20] (1996) 90 French Id patients
with HIV infection
13 ssu-rRNA (nr): L. donovani 98 98 100
Andresen et al. [21] (1997) 40 Sudanese patients 40 kDNA (800 bp):
L. donovani
92.5b 100 100
Osman et al. [22] (1997) 492 Sudanese patients 47 ssU-rRNA (nr): Leishmania
species
70c 100 100
Katakura et al. [11] (1998) 13 Chinese patients
(including 12
children)
13 n-PCR mini-exon gene
(450 bp): L. donovani
NRd 83.3 100
Singh et al. [23] (1999) 100 Indian patients 17 kDNA (204 bp):
L. donovani
82.3 NR 100
Lachaud et al. [7] (2000) 237 French patients 36e ssU-rRNA (603 bp):
L. infantum
97 100 100
Campino et al. [24] (2000) 24 Portuguese pa-
tients (18 with HIV
infection)
20 ssU-rRNA (600 bp):
L. infantum
75f NR NR
Hu et al. [25] (2000) 22 Chinese patients 22 kDNA (297bp):
L. donovani
68.8 91 100
Salotra et al. [26] (2001) 51 Indian patients 51 kDNA (792 bp):
L. donovani
96 100 96
Pizzuto et al. [9] (2001) 76 Italian adult HIV-in-
fected patients
10 ssU-rRNA (359 bp):
L. infantum
100 100 100
Fisa et al. [27] (2002) 45 Spanish HIV-in-
fected patients (2
were uninfected)
33 n-PCR (100 bp):
L. infantum
100 100 100
Cruz et al. [28] (2002) 89 Spanish Id, HIV-in-
fected adults
44 ssU-rRNA n-PCR (358 bp):
L. infantum
95.4 100 100
Cascio et al. [14] (2002) 14 Italian Ic children 10 ssU-rRNA (359 bp):
L. infantum
100 100 100
Martin-Sanchez et al. [29] (2002) 56 Spanish patients
(13 with HIV
infection)
24 kDNA- Elisa (nr):
L. infantum
100 67 100
Disch et al. [30] (2003) 68 Brazilian Ic adults 53 kDNA (120 bp):
Leishmania chagasi
91 NR 100
Deniau et al. [31] (2003) 69 French HIV-infected
patients
14 nDNA (250 bp):
Leishmania species
86 93 100
Bossolasco et al. [32] (2003) 25 Italian Id, HIV-in-
fected adults
10 ssU-rRNA real-time:
L. infantum
100 NR 100
Fissore et al. [33] (2004) 21 French Ic adults
and children and 12
French Id patients
(10 with HIV infec-
tion, 1 with BmT,
and 1 with Ly)
33 kDNA (139 bp):
L. infantum
NRg NR 95
Cortes et al. [34] (2004) 22 Portuguese
patients
8 kDNA (447 bp):
L. infantum
NR 100 100
Gatti et al. [35] (2004) 22 Italian Id patients
(12 with HIV infec-
tion, 4 with Sot, and
6 with mal) and 20
Italian Ic adults
41 ssU-rRNA (215 bp):
Leishmania species
93.3 for Ic patients
and 100 for Id patients
NR 100
(continued)
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Table 2. (Continued.)
Study (year) Study cohort
No. of
patients
with VL
Type of PCR (bp):
Leishmania species
Sensitivity of PCR, %
Specificity,
%Whole blood specimen
BMA
specimen
Pal et al. [36] (2004) 20 Indian patients 14 kDNA (790 bp):
Leishmania species
100 83 100
Da Silva et al. [37] (2004) 85 Brazilian patients 85 kDNA (120 bp): L. chagasi 84.7 100 100
De Doncker et al. [38] (2005) 99 Nepalese Ic adults 56 ssU-rRNA 73.2 by conventional PCR
and 83.9 by ELISA PCR
NR 87.2
Maurya et al. [39] (2005) 251 Indian patients 101 kDNA (600 bp):
L. donovani
99 NR 100
Cruz et al. [40] (2006) 25 Spanish children 25 ssU-rRNA n-PCR (358 bp):
L. infantum
79 100 100
NOTE. BMA, bone marrow aspirate; BmT, bone marrow transplant; bp, base pair; Ic, immunocompetent; Id, immunodepressed; kDNA, kinetoplast DNA; Ly,
lymphoma; mal, malignancy; medRNA, multicopy mini-exon RNA; n-PCR, nested PCR; NR, not reported; Ra, rheumatoid arthritis; Sot, solid organ transplant;
ssU-rRNA, small subunit ribosomal RNA.
a Sensitivity of PCR of whole blood specimens was 80% for Brazilian patients, 90% for Indian patients, and 100% for Kenyan patients.
b Sensitivity of PCR of lymph node samples was 100%.
c Sensitivity of PCR of lymph node samples was 86.8%.
d Sensitivity of PCR of buffy coat was 53.8%.
e Seven Ic adults, 5 Ic children, and Id adults (15 with HIV infection, 3 with Sot, and 1 with Ra).
f Overall sensitivity was 95.5%.
g Sensitivity of PCR of serum was 97%.
9]. Molecular identification of Old World Leishmania species
was performed by restriction fragment–length polymorphism
analysis of a PCR-amplified specific nuclear repetitive genomic
sequence, exactly as described by Minodier et al. [12].
In vitro isolation. Leishmania cultures were performed by
seeding BMA specimens in blood agar media (Evans modified,
Tobie’s medium, and/or Sloppy Evans medium). Positive cul-
ture results were further characterized by the electrophoretic
analysis of 15 enzymatic loci, using the techniques and zym-
odeme nomenclature of the World Health Organization Col-
laborating Centre of Montpellier [13].
Serologic testing. The serologic diagnosis was performed
by indirect immunofluorescence antibody (the threshold titer
for positivity was 140), using an in-house manufactured an-
tigen preparation from the World Health Organization refer-
ence strain of L. infantum or a commercial kit (Leishmania spot
IF; BioMe`rieux). In particular, serologic testing of samples from
all children was performed with the in-house preparation at
the Laboratorio di Parassitologia at the Istituto Superiore di
Sanita` (Rome, Italy). All of the other samples were analyzed
with the commercial kit.
Statistical analysis was performed using the Mann-Whitney
U test. All P values .05 were considered to be statistically
significant. This study followed the appropriate Italian ethical
requirements and was approved by the local ethical committees.
The parents gave informed consent before the enrollment of
their children in the study.
RESULTS
During the study, a total of 1678 samples (1483 PB samples
and 195 BMA samples) obtained from 594 patients were pro-
cessed for Leishmania DNA PCR at our laboratory, either for
the primary diagnosis or the follow-up of VL.
Overall, 68 patients (11.4%) received a diagnosis of VL, in-
cluding 11 HIV-uninfected adults (group A), 20 HIV-infected
adults (group B), and 37 immunocompetent HIV-uninfected
children (group C) (table 1). Preliminary results of examination
of 10 HIV-positive patients and 10 immunocompetent children
in this series have been previously reported [9, 14]. Among the
447 HIV-infected patients, 89 had atypical mycobacteriosis, 67
had disseminated and/or pulmonary tuberculosis, 49 had non-
Hodgkin lymphoma, 49 had bacterial sepsis, 31 had pneu-
mocystosis, 27 had Kaposi sarcoma, 23 had disseminated cy-
tomegalovirus disease, 76 had other infectious or neoplastic
diseases, and 36 had an unidentified cause of fever. Among the
HIV-uninfected adult patients, 23 had non-Hodgkin lym-
phoma, 12 had Hodgkin lymphoma, 8 had autoimmune dis-
eases, 4 had acute leukemia, and 11 had an unidentified cause
of fever. Among the remaining 18 pediatric patients, 13 had
acute leukemia, 2 had infectious mononucleosis, and 3 had
non-Hodgkin lymphoma.
A total of 536 PB samples and 74 BMA samples from patients
with confirmed VL were available for investigation by PCR
during the study period. Specimens were distributed as follows:
69 PB specimens (range, 2–16 specimens per patient) and 6
BMA specimens (range, 1–2 specimens per patient) for group
A, 306 PB specimens (range, 1–101 specimens per patient) and
24 BMA specimens (range, 1–4 specimens per patient) for
group B, and 159 PB specimens (range, 2–15 specimens per
patient) and 44 BMA specimens (range, 1–3 specimens per
patient) for group C. Overall, the sensitivity of PCR in the
primary diagnosis of VL was 95.7% (for BMA specimens) and
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Figure 1. Proposed clinical algorithm for the use of PCR in the primary diagnosis of visceral leishmaniasis. Leishmania serologic testing in
immunocompromised patients is generally of little value, especially if performed with commercial kits, and, therefore, should be used as initial screening
only in immunocompetent patients. Leishmania PCR, when available, has been shown to be extremely sensitive and specific, and it should be used
to confirm the primary diagnosis of VL. Bone marrow aspirate (BMA) samples should be obtained only when PCR of a peripheral blood (PB) sample
is negative for VL, to definitively exclude VL or to make an alternative diagnosis.
98.5% (for PB specimens). In all of the cases, the diagnosis of
VL was obtained from a single initial sample.
On the other hand, the sensitivities of in vitro isolation,
Leishmania serologic testing, and microscopic examination of
BMA samples were 76.2%, 85.5%, and 90.2%, respectively (ta-
ble 1). In all of the study groups, PCR of PB samples exhibited
the highest sensitivity, ranging from 97.1% (in group C) to
100% (in groups A and B ). Leishmania DNA was not detected
by PCR in any sample from a negative control subject (i.e.,
229 blood donors and 25 patients with imported malaria);
therefore, the specificity of the assay was assumed to be 100%.
At diagnosis of primary VL, the median Leishmania DNA
burden was higher in BMA samples than in PB samples (P !
). In more detail, HIV-uninfected adults exhibited a 2 log10.001
higher parasite load in BMA samples, compared with that in
PB samples ( ), and HIV-infected adults had comparablePp .01
levels of Leishmania DNA in the 2 anatomical districts. In HIV-
negative children, the median Leishmania DNA levels were 1
log10 higher in BMA samples ( ). Finally , significantlyPp .001
higher levels of parasitaemia were observed in adults than in
children ( ).P ! .009
Fifty-four patients were prospectively monitored using se-
miquantitative PCR of PB samples during periods ranging from
1 to 84 months (median duration, 6 months). In particular,
median periods of molecular monitoring were 3 months for
patients in group A, 13 months for patients in group B, and
6 months for patients in group C.
Clinical and parasitologic relapses were detected in 13 of 54
individuals, including 11 adults with AIDS (55%) and 2 HIV-
uninfected children (5%; ). In particular, 4 subjects withP ! .001
HIV infection experienced multiple relapses (range, 2–6 re-
lapses). No recrudescences of VL were observed in HIV-un-
infected adult patients (group A).
Immunocompetent children and adults cleared Leishmania
DNA from PB within a few days from the start of treatment
(median duration, 9 and 12 days, respectively). By contrast, the
duration of time to Leishmania PCR negativity following the
first cycle of specific therapy was consistently longer in indi-
viduals coinfected with HIV (median duration, 17.5 days). In
particular, 4 (23.5 %) of 17 HIV-infected patients had unde-
tectable Leishmania DNA in PB within 8 days from the start
of treatment; 5 of these patients cleared Leishmania DNA within
5 weeks, 4 patients cleared Leishmania DNA within 8 weeks,
and the remaining 3 patients cleared Leishmania DNA within
21 weeks.
Results of Leishmania PCR of PB samples reverted to positive
in 11 HIV-infected patients, 7 of whom thereafter had persis-
tently positive results during the follow-up period (median du-
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ration, 21 months; range, 3–72 months). Six of these 7 patients
experienced at least 1 relapse of VL during the follow-up period.
PCR and restriction fragment-length polymorphism analysis
for Leishmania species identification was performed for all pa-
tients with the following results: 10 patients had L. infantum
infection and 1 patient had L. donovani infection in group A,
16 patients had L. infantum infection and 4 patients had L.
donovani infection in group B, and 37 patients had L. infantum
infection in group C. One hundred percent perfect concordance
was observed with the isoenzyme typing method in the 19
patients for whom the method was available (1 patient had L.
infantum infection and 1 patient had L. donovani infection in
group A, 2 patients had L. donovani infection in group B, and
15 patients had L. infantum infection in group C).
DISCUSSION
The application of PCR to detect parasite DNA for the diagnosis
of cutaneous leishmaniasis and VL in tissues has been reported
since the early 1990s [5, 10]. The use of PCR of PB samples
to diagnose VL was first reported in 1995 by 4 investigators
[15–18] who employed this technique in patients with con-
firmed VL in India [15, 16], Brazil, Kenya [16, 18], and Swit-
zerland (the patients in Switzerland had imported disease) [17].
Since then, at least 29 studies have been published with the
description of different protocols that use, as the target of PCR
amplification, either the Leishmania kinetoplast DNA minicir-
cle, which is present at thousands of copies per parasite [16,
21, 23, 25–27, 29, 30, 31, 33, 34, 36, 37, 39, 41] , or the small
subunit rRNA gene, which is repeated 1100 times in the Leish-
mania genome [6, 9, 14, 17, 20, 22, 24, 28, 32, 35, 38, 40]
(table 2).
In our study, we chose the small subunit rRNA gene of the
parasite as the target sequence. The primers were those origi-
nally described by van Eys et al. [4], which have been shown
to specifically amplify all known human pathogenic Leishmania
species.
When compared with serologic testing, in vitro culture, and
direct bone marrow examination, the PCR performed on whole
blood samples appeared, in our study, to be more sensitive,
with an overall sensitivity of 98.5%, considering all categories
of patients studied. Moreover, the PCR of PB samples per-
formed slightly better than PCR of BMA samples with regard
to sensitivity (98.5% vs. 95.7%). Our results are in good agree-
ment with those reported by several investigators who studied
different groups of French, Spanish, and Indian patients [7, 26,
28, 33, 39]. However, in some other studies, the sensitivity of
PCR of PB samples was unsatisfactory, ranging from as low as
54% (in a small study performed with Chinese children [11])
to 70%–85% [22–25, 37, 38, 40]. These discrepancies have been
ascribed either to differences in the volume of blood tested in
the PCR [22], to differences in the timing of sample collection
[6, 15, 22], or to differences pertaining to the species of Leish-
mania parasites, some of which may indeed circulate less fre-
quently or at lower levels in the infected host [22]. In addition,
in a study by Singh et al. [23], it was speculated that some
patients with negative results of PCR of PB samples might have
undergone a previous private treatment before admission to
the hospital. Finally, in at least 2 studies, the use of blood
samples spotted on filter paper might have negatively influenced
the results [26, 39].
It is also worth noting that the sensitivity of Leishmania PCR
of PB samples was superior to all the conventional diagnostic
techniques in HIV-infected and HIV-uninfected adults but was
inferior to serologic testing in HIV-negative children (sensitivity
of PCR of PB samples vs. sensitivity of serologic testing, 97.1%
vs. 100%). A high sensitivity of Leishmania serologic testing
was also recently reported by Cruz et al. [40] in a study in-
volving 25 Spanish children. However, in the same study, the
authors reported a lower sensitivity of Leishmania PCR of PB
samples, compared with our present and past experience [14].
The specificity of our PCR assay was also excellent (100%),
because no false-positive result was obtained either in the neg-
ative control tubes or from negative control patients. Overall
specificities of 100% were reported in 23 of 28 studies [7, 9,
11, 14–17, 20–23, 25, 27–30, 32, 34–37, 39, 40], with the lowest
values being those reported in the study by De Doncker et al.
[38]. Of note, De Doncker et al. [38] found a 100% specificity
using Belgian blood donors as negative controls, compared with
87.2% specificity when individuals living in an area where VL
was endemic were used as negative controls.
It is generally accepted that, in patients with VL, the parasite
load in PB samples is lower than that in BMA samples [7]. In
addition, it is commonly believed that the parasite burden in
immunocompetent patients is lower than that in patients with
VL and concomitant HIV infection [32, 38]. However, these
assumptions are thus far only speculative and, to our knowl-
edge, have not been formally demonstrated. The hypothesis
that higher levels of parasitaemia occur in HIV-infected patients
was indirectly inferred by the observation that, in these patients,
Leishmania parasites could be readily isolated from PB samples
[41]. In our study, using semiquantitative PCR, we demon-
strated that, if we considered all patients, irrespective of age
and immune status, the median parasite DNA load detected in
BMA samples was 10 times higher than that detected in PB
samples. This is also confirmed by the analysis of HIV-unin-
fected children and adults. However, HIV-infected patients did
not have statistically significant differences in parasite burden
measured in simultaneously obtained PB and BMA samples.
In addition, the parasite load detected in PB samples was sig-
nificantly higher in HIV-infected patients than in HIV-unin-
fected children but was not significantly higher in HIV-infected
patients than it was in HIV-uninfected adults.
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With regard to the usefulness of PCR in the monitoring of
patients undergoing specific treatment, to date, 13 studies have
been published [7, 9, 14, 16, 22, 27, 28, 30, 32, 35, 39–41], of
which only 7 have specifically addressed the issue [7, 9, 14, 28,
30, 39, 41] (table 3). Immunocompetent patients rapidly clear
Leishmania DNA from peripheral blood [14, 16, 30, 39], con-
firming a good concordance between clinical cure and PCR
results. However, few possible exceptions to the rule have been
reported [30, 39].
On the other hand, patients with VL and concomitant HIV
infection have a completely different course of Leishmania
DNAemia while receiving specific therapy. Indeed, the majority
of HIV-infected patients do not clear Leishmania DNA from
PB [9, 27,28, 32] or show a rapid reappearance of Leishmania
DNA when specific therapy is interrupted. Both situations are
generally—albeit, not invariably—associated with clinical re-
lapse [28, 42]. It remains to be determined if it will be possible
to define a cutoff value for Leishmania DNAemia that will allow
researchers to predict the future development of clinical relapses
of the disease in HIV-infected patients.
Isoenzyme analysis is currently considered to be the gold
standard for the differentiation of Leishmania parasites at the
species level, but this technique is laborious and time-consum-
ing, is available only in a few laboratories, and, above all, re-
quires prior isolation of the parasite. In our study, using a PCR
and restriction fragment–length polymorphism protocol that
was originally described by Minodier et al. [12], we readily
identified, at the species level, all 68 cases of VL. Interestingly,
we identified 5 cases of VL in which L. donovani was implicated.
The first case was observed in a immunocompetent Italian
patient who had lived and traveled in India for 7 years, and
the remaining 4 cases occurred in HIV-infected intravenous
drug users. In 2 of the latter cases, no evidence of travel history
to areas where L. donovani is endemic was found, which lends
support to the hypothesis of the introduction of the parasite
in parenteral drug users through the artificial epidemic cycle
[43]. Finally, for the 19 cases for which standard isoenzyme
characterization of Leishmania species was available, we found
perfect concordance between the 2 techniques that we used.
Thus, molecular characterization of Leishmania species may
overcome the need for parasite isolation. However, it should
be noted that the PCR and restriction fragment–length poly-
morphism protocol we used in our study is unable to discrim-
inate, at the species level, Leishmania parasites of the New World
belonging to Leishmania braziliensis (e.g., Leishmania brazil-
iensis and Leishmania peruviana) and the Leishmania guyanensis
complex (e.g., Leishmania guyanensis and Leishmania
panamensis).
In summary, on the basis of the results of our study and of
previous reports, we propose the algorithm reported in figure
1 for the primary diagnosis of VL in patients presenting with
fever, hepatosplenomegaly, and pancytopenia. Because the di-
agnostic yield of PB appears to be at least equivalent to that
of BMA when Leishmania PCR is used in both immunocom-
promised and immunocompetent patients, few justifications
remain to perform first-line BMA in clinical practice when the
diagnosis of VL is suspected.
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